Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE: ABBV) and its peers.
Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 11 therapeutics stocks we track reported a very strong Q2. As a group, revenues beat analysts’ consensus estimates by 8%.
Luckily, therapeutics stocks have performed well with share prices up 24.8% on average since the latest earnings results.
AbbVie (NYSE: ABBV)
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
AbbVie reported revenues of $16.99 billion, up 10.2% year on year. This print exceeded analysts’ expectations by 1.2%. Despite the top-line beat, it was still a mixed quarter for the company with a narrow beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.
Interestingly, the stock is up 2.9% since reporting and currently trades at $264.79.
Is now the time to buy AbbVie? Access our full analysis of the earnings results here, it’s free.
Best Q2: Biogen (NASDAQ: BIIB)
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ: BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Biogen reported revenues of $2.74 billion, up 3.4% year on year, outperforming analysts’ expectations by 12.1%. The business had an incredible quarter with a solid beat of analysts’ full-year EPS guidance estimates.
The market seems happy with the results as the stock is up 6.6% since reporting. It currently trades at $219.17.
Is now the time to buy Biogen? Access our full analysis of the earnings results here, it’s free.
Weakest Q2: Myriad Genetics (NASDAQ: MYGN)
Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.
Myriad Genetics reported revenues of $190.7 million, down 10.5% year on year, falling short of analysts’ expectations by 8.2%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts’ expectations and a significant miss of analysts’ EPS estimates.
Myriad Genetics delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 25.3% since the results and currently trades at $4.01.
Read our full analysis of Myriad Genetics’s results here.
Gilead Sciences (NASDAQ: GILD)
From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ: GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
Gilead Sciences reported revenues of $7.80 billion, up 10.2% year on year. This print beat analysts’ expectations by 6.2%. Overall, it was a very strong quarter as it also logged a solid beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
The stock is up 10.4% since reporting and currently trades at $149.30.
Read our full, actionable report on Gilead Sciences here, it’s free.
Moderna (NASDAQ: MRNA)
Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ: MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.
Moderna reported revenues of $145 million, up 2.1% year on year. This result surpassed analysts’ expectations by 35.8%. Overall, it was an exceptional quarter as it also produced a beat of analysts’ EPS estimates.
Moderna delivered the biggest analyst estimate beat of the whole group. The stock is up 199% since reporting and currently trades at $172.89.
Read our full, actionable report on Moderna here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
